All In Biotech

Drug Trial Radar · NCT07948395

Improving Vaccine Efficacy for People With Helminth Infection: CORBEVAX in Ethiopia

Immunogenicity of the CpG 1018-Adjuvanted CORBEVAX COVID-19 Vaccine in Adults With and Without Helminth Infection (Schistosoma Mansoni or Hookworm) in Ethiopia

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Apr 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Biological E. Limited; Debre Markos University
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Helminth infections affect over 1.5 billion people and weaken the response to vaccination. CORBEVAX contains the TLR9-activating adjuvant CpG 1018, which may overcome this. This trial measures the immunogenicity of CORBEVAX in adults with and without Schistosoma mansoni or hookworm infection in Ethiopia. The primary measure is spike-specific serum IgG at Day 42; antibody subclass, T-cell, neutralisation and regulatory T-cell responses are measured as secondary outcomes up to Day 90. This is the first of two planned cohorts under a shared protocol; a second cohort receiving an mRNA COVID-19 vaccine at the same sites is planned subject to vaccine availability and will be registered separately.

Conditions

  • Schistosomiasis Mansoni
  • Hookworm Infection
  • COVID-19

Interventions

  • Biological: CORBEVAXBiological

    Recombinant SARS-CoV-2 receptor-binding-domain protein subunit vaccine adjuvanted with CpG 1018 and alum (Biological E Limited). Two intramuscular doses(0.5 ml/dose), Day 0 and Day 28 (±3 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean concentration of serum anti-SARS-CoV-2 spike IgG, by helminth infection statusTime frame: Day 42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andasa Health Centre

    Bahir Dar, Amhara, Ethiopia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.